Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast versus placebo added to fixed LABA/ICS therapy in severe COPD
2010-019685-87Phase 4Completed
- Sponsor
- Takeda
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Roflumilast + fixed LABA/ICS with Placebo + fixed LABA/ICS (2 arms). Primary endpoint: Rate of moderate or severe COPD exacerbations per patient per year. Started Feb 2011; status: completed.
02
Drugs
roflumilast
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2010-019685-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019685-87.